Apimeds Pharmaceuticals US FY 2025: Revenue $0 Net loss $6M, EPS $(0.55) — 10-K Summary

Apimeds Pharmaceuticals US, Inc. reported a net loss of $6M for fiscal 2025 on revenue of $0 compared with a net loss of $1.4M and no revenue in fiscal 2024; diluted loss per share was $(0.55) in 2025 based on 10.88M weighted‑average shares — 10-K Summary.Financial HighlightsRevenue was $0 for FY 2025 and FY 2024 (no revenue from biopharmaceutical or MindWave operations).Net income: Net loss of $6.0M for FY 2025, compared with net loss of $1.4M for FY 2024.Diluted earnings per share: $(0.55) per share for FY 2025 (basic and diluted), based on 10.88M weighted‑average shares.Business HighlightsIPO and public listing: Completed NYSE IPO on May 12, 2025, providing public market access and approximately $11.6M in net proceeds to support operations.Strategic merger expansion: Acquired MindWave on Dec. 1, 2025, creating a dual‑segment company that adds digital asset operations and blockchain ecosystem management.Operational scale‑up: Ramped biopharma activities in 2025, with $1.6M in R&D spend, CRO engagements, and $2M in prepaid clinical services for Apitox trials.Digital asset monetization & activity: Realized and unrealized gains from NILA token sales and BTC holdings bolstered non‑operating income and provided additional liquidity options.Near‑term funding and clinical plan: Management intends to draw remaining PIPE tranches, continue token sales, and advance Apitox manufacturing and clinical work through 2026.Original SEC Filing: Apimeds Pharmaceuticals US, Inc. [ APUS ] - 10-K - May. 04, 2026DisclaimerThis is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.